KPIs & Operating Metrics(New)
Aesthetics Revenue By CategoryAesthetics Revenue By Category AnnualAesthetics Revenue By GeographyAesthetics Revenue By Geography AnnualBreakdown Of AssetsEmployee StatisticsEye Care Revenue By CategoryEye Care Revenue By Category AnnualEye Care Revenue By GeographyEye Care Revenue By Geography AnnualGross MarginGross Margin %Gross Margin AnnualGross Margin Annual %Hematology Oncology Revenue By CategoryHematology Oncology Revenue By Category AnnualHematology Oncology Revenue By GeographyHematology Oncology Revenue By Geography AnnualImmunology Revenue By CategoryImmunology Revenue By Category AnnualImmunology Revenue By GeographyImmunology Revenue By Geography AnnualIncome Before Income Taxes By RegionLong Lived Assets By RegionNeuroscience Revenue By CategoryNeuroscience Revenue By Category AnnualNeuroscience Revenue By GeographyNeuroscience Revenue By Geography AnnualNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Opex As A % Of RevenueOPEX SegregationOther Key Products Revenue By CategoryOther Key Products Revenue By Category AnnualOther Key Products Revenue By GeographyOther Key Products Revenue By Geography AnnualProperty & Equipment BreakdownRevenueRevenue By GeographyRevenue By Geography %Revenue By Geography AnnualRevenue By Geography Annual %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %Revenue By Ship To LocationRevenue By Ship To Location %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AbbVie (ABBV) Revenue (2016 - 2025)

AbbVie (ABBV) has disclosed Revenue for 14 consecutive years, with $16.6 billion as the latest value for Q4 2025.

  • On a quarterly basis, Revenue rose 10.04% to $16.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $61.2 billion, a 8.57% increase, with the full-year FY2025 number at $61.2 billion, up 8.57% from a year prior.
  • Revenue was $16.6 billion for Q4 2025 at AbbVie, up from $15.8 billion in the prior quarter.
  • In the past five years, Revenue ranged from a high of $16.6 billion in Q4 2025 to a low of $12.2 billion in Q1 2023.
  • A 5-year average of $14.3 billion and a median of $14.4 billion in 2021 define the central range for Revenue.
  • Peak YoY movement for Revenue: skyrocketed 50.95% in 2021, then fell 9.7% in 2023.
  • AbbVie's Revenue stood at $14.9 billion in 2021, then increased by 1.58% to $15.1 billion in 2022, then dropped by 5.42% to $14.3 billion in 2023, then grew by 5.6% to $15.1 billion in 2024, then grew by 10.04% to $16.6 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Revenue are $16.6 billion (Q4 2025), $15.8 billion (Q3 2025), and $15.4 billion (Q2 2025).